Media
Dr. Zhang Yi Honored as Shanghai Model and Advanced Worker
May 13, 2025 - Shanghai, China
On May 9, at the Commendation Conference for Model Collectives, Model Workers, and Advanced Workers in Shanghai, Dr. Zhang Yi, the Senior Vice President of the Drug Development Department and Chief Medical Officer of Hua Medicine, was honored as a "Shanghai Model Worker and Advanced Worker" for her outstanding contributions in the field of medical research and development. This honor is selected every five years to commend workers from all walks of life and various economic types of units who have made outstanding contributions to the political, economic, cultural, social, ecological civilization, and Party construction in Shanghai.
Swipe left or right to view more
Dr. Zhang Yi has a profound professional background and rich practical experience in the pharmaceutical industry. Before joining Hua Medicine, she had more than 10 years of clinical experience and presided over several National Natural Science Foundation of China and Shanghai Natural Science Foundation projects. Subsequently, she joined the Clinical Science Department of the former Roche Asia-Pacific R&D Center and dedicated herself to the field of innovative drug research and development.
Dr. Zhang Yi joined Hua Medicine in 2013. Starting from the phase I, first-in-human study, with her rigorous scientific attitude, she led the team to participate in the entire process of the clinical research and development of dorzagliatin, world's first innovative glucokinase activator drug. This laid the foundation for the successful launch of dorzagliatin, and promoted the transformation of the scientific concept of "repairing the sensor, restoring the homeostasis, and treating the underlying cause of diabetes" into a new treatment plan for diabetic patients in China and even around the world. In 2023, Dr. Zhang Yi participated in the national medical insurance negotiation on behalf of Hua Medicine. In 2024, dorzagliatin officially began to be sold under the medical insurance system, greatly improving the accessibility and affordability for patients.
At present, Dr. Zhang Yi is leading the team to carry out post - marketing research on dorzagliatin, further verifying its potential in personalized diabetes treatment, as well as in the prevention and remission of diabetes. At the same time, she is promoting research on the combined use of dorzagliatin with GLP-1R agonists, DPP-4 inhibitors, and SGLT-2 inhibitors.
In addition, Dr. Zhang Yi is also actively involved in social affairs. She is currently a member of the Pudong New Area Political Consultative Conference, a representative of the Shanghai Women's Federation Congress, and the vice chairperson of the Zhangjiang Science City Women's Federation. She has successively won honors such as the "Shanghai May 1st Labor Medal", "Shanghai Female Achiever Pace - setter", and "Shanghai Outstanding Technology Leader".
Dr. Zhang Yi's award is the pride of Hua Medicine and also inspires all employees to keep forging ahead on the path of innovative research and development. In the future, Hua Medicine will continue to delve deeply into the field of innovative drug research and development and make greater contributions to improving the health level of mankind.
About Hua Medicine
Hua Medicine (The "Company") is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (华堂宁®) (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing (华堂宁®) was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.
For more information
Hua Medicine
Website: www.huamedicine.com
Investors
E-mail: ir@huamedicine.com
Media
E-mail: pr@huamedicine.com
沪ICP备14036654号-1
沪公网安备 31011502013809号 Privacy Statement Terms of Use
